Occam Places R&D Leader David Mauro as CMO at Recursion

Recursion (NASDAQ: RXRX), a leading TechBio company decoding biology to industrialize drug discovery, today announced the appointment of David Mauro, M.D., Ph.D, as Chief Medical Officer.  In this key role, Mauro will orchestrate and curate Recursion’s pipeline, including the five programs currently in the clinic.

‍

David is a broadly accomplished executive.  His history manifests a pleasing combination of strategic vision with a tactile, detailed, and disciplined sense of what is required to develop a drug.  Mauro’s extensive professional background includes the selection and cultivation of large and small molecules, effectiveness across modalities in oncology, and successful leadership in both large and small organizations.

‍

Mauro brings to Recursion over 20 years in oncology R&D.  His notable accomplishments include guiding the translational, preliminary, and later stages of development for more than 25 IND candidates over the past decade.  His prior roles have involved serving as the Chief Medical Officer for Codiak BioSciences, Checkmate Pharmaceuticals, Prelude Therapeutics, and Advaxis. Previously,  Dr. Mauro has also held executive roles at Merck and  Bristol Myers Squibb.

Mauro received a B.S. in Biochemistry from Cornell University and an M.D./Ph.D. from Temple University. He completed his residency in anatomic pathology at the National Cancer Institute.

‍

Read more about Occam's work with Recursion in our case study.